Several multigene assays that evaluate the prognosis or the benefit of adjuvant chemotherapy for hormone receptor (HR)-positive, HER2-negative early-stage breast cancer, are commercially available and widely used in clinical practice (36). This evidence concerns the gene NR4A1 and breast cancer.